NASDAQ:ALNA - Allena Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.88 -0.03 (-0.61 %) (As of 05/23/2019 09:46 AM ET)Previous Close$4.91Today's Range$4.88 - $4.8852-Week Range$4.80 - $16.13Volume1,178 shsAverage Volume62,514 shsMarket Capitalization$101.60 millionP/E RatioN/ADividend YieldN/ABeta1.69 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts. Receive ALNA News and Ratings via Email Sign-up to receive the latest news and ratings for ALNA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALNA Previous Symbol CUSIPN/A CIK1624658 Webhttp://www.allenapharma.com/ Phone617-467-4577Debt Debt-to-Equity Ratio0.24 Current Ratio7.83 Quick Ratio7.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.86 per share Price / Book2.62Profitability EPS (Most Recent Fiscal Year)($1.72) Net Income$-35,650,000.00 Net MarginsN/A Return on Equity-73.27% Return on Assets-57.31%Miscellaneous Employees49 Outstanding Shares20,820,000Market Cap$101.60 million Next Earnings Date8/6/2019 (Estimated) OptionableNot Optionable Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions What is Allena Pharmaceuticals' stock symbol? Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA." How were Allena Pharmaceuticals' earnings last quarter? Allena Pharmaceuticals Inc (NASDAQ:ALNA) released its earnings results on Wednesday, May, 8th. The company reported ($0.55) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.06. View Allena Pharmaceuticals' Earnings History. When is Allena Pharmaceuticals' next earnings date? Allena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Allena Pharmaceuticals. What price target have analysts set for ALNA? 6 brokerages have issued 1-year target prices for Allena Pharmaceuticals' shares. Their predictions range from $20.00 to $39.00. On average, they anticipate Allena Pharmaceuticals' share price to reach $25.20 in the next year. This suggests a possible upside of 416.4% from the stock's current price. View Analyst Price Targets for Allena Pharmaceuticals. What is the consensus analysts' recommendation for Allena Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allena Pharmaceuticals. What are Wall Street analysts saying about Allena Pharmaceuticals stock? Here are some recent quotes from research analysts about Allena Pharmaceuticals stock: 1. According to Zacks Investment Research, "Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which are in clinical stages. Allena Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. " (5/15/2019) 2. Cowen Inc analysts commented, "We expect SEL-212 to show (1) superior efficacy, (2) better safety, and (3) less frequent dosing vs Krystexxa in the head-to-head study, giving SEL-212 a major commercial advantage." (8/8/2018) Has Allena Pharmaceuticals been receiving favorable news coverage? News headlines about ALNA stock have been trending very negative recently, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allena Pharmaceuticals earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of Allena Pharmaceuticals' key competitors? Some companies that are related to Allena Pharmaceuticals include Agenus (AGEN), Adaptimmune Therapeutics (ADAP), Avrobio (AVRO), Gritstone Oncology (GRTS), BioCryst Pharmaceuticals (BCRX), PDL BioPharma (PDLI), LogicBio Therapeutics (LOGC), Axcella Health (AXLA), CASI Pharmaceuticals (CASI), Cellular Biomedicine Group (CBMG), Harpoon Therapeutics (HARP), Sutro Biopharma (STRO), Eiger Biopharmaceuticals (EIGR), X4 Pharmaceuticals (XFOR) and Solid Biosciences (SLDB). What other stocks do shareholders of Allena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Viking Therapeutics (VKTX), Exelixis (EXEL), Fate Therapeutics (FATE), Pieris Pharmaceuticals (PIRS), Clearside Biomedical (CLSD), Sorrento Therapeutics (SRNE), Ampliphi Biosciences (APHB), Arrowhead Pharmaceuticals (ARWR), Deciphera Pharmaceuticals (DCPH) and Editas Medicine (EDIT). Who are Allena Pharmaceuticals' key executives? Allena Pharmaceuticals' management team includes the folowing people: Dr. Alexey L. Margolin, Co-Founder & Chairman (Age 66)Dr. Louis Brenner, Pres, CEO & Director (Age 49)Mr. Edward J. Wholihan, CFO and VP of Fin. & Admin. (Age 59)Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 54)Mr. Hugh Wight, Sr. VP of Technical Operations When did Allena Pharmaceuticals IPO? (ALNA) raised $80 million in an IPO on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Allena Pharmaceuticals' major shareholders? Allena Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Morgan Stanley (8.58%), BlackRock Inc. (2.92%), JPMorgan Chase & Co. (1.05%), Dimensional Fund Advisors LP (0.29%), Jacobs Levy Equity Management Inc. (0.17%) and Charles Schwab Investment Management Inc. (0.14%). Company insiders that own Allena Pharmaceuticals stock include Bessemer Venture Partners Vii and James N Topper. View Institutional Ownership Trends for Allena Pharmaceuticals. Which institutional investors are selling Allena Pharmaceuticals stock? ALNA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, JPMorgan Chase & Co., Oxford Asset Management LLP and New York State Common Retirement Fund. View Insider Buying and Selling for Allena Pharmaceuticals. Which institutional investors are buying Allena Pharmaceuticals stock? ALNA stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Jacobs Levy Equity Management Inc., BlackRock Inc., Renaissance Technologies LLC, Wells Fargo & Company MN, Charles Schwab Investment Management Inc. and State of Wisconsin Investment Board. Company insiders that have bought Allena Pharmaceuticals stock in the last two years include Bessemer Venture Partners Vii and James N Topper. View Insider Buying and Selling for Allena Pharmaceuticals. How do I buy shares of Allena Pharmaceuticals? Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Allena Pharmaceuticals' stock price today? One share of ALNA stock can currently be purchased for approximately $4.88. How big of a company is Allena Pharmaceuticals? Allena Pharmaceuticals has a market capitalization of $101.60 million. The company earns $-35,650,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Allena Pharmaceuticals employs 49 workers across the globe. What is Allena Pharmaceuticals' official website? The official website for Allena Pharmaceuticals is http://www.allenapharma.com/. How can I contact Allena Pharmaceuticals? Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577. MarketBeat Community Rating for Allena Pharmaceuticals (NASDAQ ALNA)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 129 (Vote Outperform)Underperform Votes: 132 (Vote Underperform)Total Votes: 261MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: What is the Consumer Price Index (CPI)? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.